According to the latest industry analysis by Future Market Insights, the global Cell Therapy Manufacturing Market Size was valued at approximately US$ 3.7 billion in 2022. The market is expected to grow at a CAGR of nearly 14.2% during the forecast period, reaching US$ 13.9 billion by 2032. Cell therapies are widely used to treat viral infections, cancer, hemoglobinopathies, and hereditary immunological disorders. The increasing research activities in this field have led to the development of reagents and closed system automated equipment for manufacturing cellular therapies.
A decentralized manufacturing model is becoming popular for clinical trials in cell therapies, involving multiple sites. Patients are treated with cells generated by automated equipment at each participating center using a single, centrally held investigational new drug application (IND). Academic institutions are investing in the development of automated devices for point-of-care manufacturing and participation in multi-center decentralized clinical trials.
Get a Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15536
As a result of these developments, the global cell therapy manufacturing market is expected to experience significant growth over the next decade. Additionally, the market’s growth will be driven by the introduction of novel therapies approved by regulatory bodies for targeted therapeutic approaches during the forecast period.
Key Takeaways from Market Study
- According to one source, the autologous segment will account for approximately 56.0% of the global market in 2021.
- The cancer indication held nearly 31.0% of the cell therapy manufacturing market in 2021.
- In terms of purpose, the clinical segment is expected to account for approximately 42.0% of the global market share in 2021.
- In 2021, the injectable route of administration of cell therapies will account for approximately 44.0% of the global market.
- In 2021, the hematopoietic stem cells (HSC) segment held a 25.0% share of the global cell therapy manufacturing market.
- The hospital settings category accounted for approximately 38.1% of the global cell therapy manufacturing market in 2021.
- China held a share of around 38.2% in 2021 in the East Asia cell therapy manufacturing market.
“Increasing number of research activities by key companies to reduce risks and get ready for a highly productive future are anticipated to drive the market. Besides, they are striving to develop innovative technologies that can assist investigators in automating their processes for gaining success in future,” says an analyst of Future Market Insights.
Avail Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-15536
Competitive Landscape: Cell Therapy Manufacturing Market
Key players in the cell therapy manufacturing market are focusing on R&D activities to initiate regenerative medicine manufacturing. Moreover, they are promoting commercial manufacturing for their clients by offering novel solutions to cell therapy developers.
For instance,
- In March 2022, Thermo Fisher Scientific presented a new large-volume electroporation system, the purpose of which is to simplify cell therapy development. The company aims to simplify transition from clinical development to commercial manufacturing among cell therapy developers.
- Charles River Laboratories’ Memphis plant became the first CDMO in North America to manufacture commercial allogeneic cell therapies after receiving European Medicines Agency (EMA) approval in August 2022.
Get Exclusive Insights on Cell Therapy Manufacturing Market
Future Market Insights offers a unique perspective and actionable insights on the cell therapy manufacturing market in its latest study, presenting a historical demand assessment of 2012 – 2021 and projections for 2022 – 2032. The global cell therapy manufacturing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Key Players:
- Merck KGaA
- Avantor, Inc.
- Cell Therapies Pty Ltd
- Thermo Fisher Scientific
- Charles River Laboratories
- Catalent, Inc
- Bio-Techne
- Cytiva
- Lonza
- The Discovery Labs
- BIOCENTRIQ
- FUJIFILM Diosynth Biotechnologies
- Novartis AG
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- WuXi AppTec.
- OXGENE
- Pharmaron
- Aldevron
- FLODESIGN SONICS
- Exothera
Customization Available@ https://www.futuremarketinsights.com/customization-available/rep-gb-15536
Key Segments Covered in Cell Therapy Manufacturing Industry
By Source:
- Autologous
- Allogenic
By Indication:
- HIV
- Autoimmune Disorders
- Immune Deficiencies
- Cancer
- Neurological Disorders
By Manufacturing Purpose:
- Clinical
- Commercial
- Pre-clinical
By Route of Administration:
- Topical
- Injectable
- Infusion
- Implantable Bio-Scaffold
By Cell Type:
- Hematopoietic (Blood-Forming) Stem Cells (HSC)
- Skeletal Muscle Stem Cells
- Mesenchymal Stem Cells
- Lymphocytes
- Dendritic Cells
- Pancreatic Islet Cells
- CAR-T Cells
By End User:
- Hospital Settings
- Intensive Outpatient Treatment Centers
- Academic and Research Institutes
- Specialty Clinics
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs